S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

Amarin Stock Forecast, Price & News

-0.01 (-0.20 %)
(As of 10/22/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.99 million shs
Average Volume4.62 million shs
Market Capitalization$1.98 billion
P/E Ratio500.50
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

Amarin logo

About Amarin

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$614.06 million
Book Value
$1.60 per share


Net Income
$-18 million




Market Cap
$1.98 billion
Next Earnings Date
11/3/2021 (Confirmed)

Social Links


Overall MarketRank

1.83 out of 5 stars

Medical Sector

749th out of 1,359 stocks

Pharmaceutical Preparations Industry

360th out of 666 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Amarin (NASDAQ:AMRN) Frequently Asked Questions

Is Amarin a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amarin stock.
View analyst ratings for Amarin
or view top-rated stocks.

What stocks does MarketBeat like better than Amarin?

Wall Street analysts have given Amarin a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amarin wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Amarin's next earnings date?

Amarin is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Amarin

How can I listen to Amarin's earnings call?

Amarin will be holding an earnings conference call on Wednesday, November 3rd at 7:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 877-481-4010 with passcode "43234".

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) released its quarterly earnings results on Wednesday, August, 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.03) by $0.05. The biopharmaceutical company had revenue of $154.50 million for the quarter, compared to the consensus estimate of $153.28 million. Amarin had a trailing twelve-month return on equity of 0.69% and a net margin of 0.70%. The business's revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.04 earnings per share.
View Amarin's earnings history

How has Amarin's stock price been impacted by COVID-19 (Coronavirus)?

Amarin's stock was trading at $12.56 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMRN shares have decreased by 60.2% and is now trading at $5.00.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AMRN?

5 Wall Street analysts have issued 12 month target prices for Amarin's stock. Their forecasts range from $5.00 to $19.00. On average, they anticipate Amarin's share price to reach $10.50 in the next year. This suggests a possible upside of 110.0% from the stock's current price.
View analysts' price targets for Amarin
or view top-rated stocks among Wall Street analysts.

Who are Amarin's key executives?

Amarin's management team includes the following people:
  • Karim Mikhail, President, Chief Executive Officer & Director
  • Derek Kalinowski, SVP-Manufacturing Operations
  • Michael W. Kalb, Chief Financial Officer & Senior Vice President (LinkedIn Profile)
  • Steven B. Ketchum, Chief Scientific Officer & Senior Vice President
  • Rebecca Juliano, Senior VP-Clinical Research & Development

What is John Thero's approval rating as Amarin's CEO?

10 employees have rated Amarin CEO John Thero on Glassdoor.com. John Thero has an approval rating of 93% among Amarin's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), (CGC), Square (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by many different institutional and retail investors. Top institutional shareholders include Private Advisor Group LLC (0.39%), Avantax Advisory Services Inc. (0.04%), Hayek Kallen Investment Management (0.04%), LCM Capital Management Inc (0.03%) and Pinnacle Associates Ltd. (0.00%). Company insiders that own Amarin stock include David M Stack, John F Thero, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum.
View institutional ownership trends for Amarin

Which major investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., and LCM Capital Management Inc. Company insiders that have sold Amarin company stock in the last year include John F Thero, Michael Wayne Kalb, and Steven B Ketchum.
View insider buying and selling activity for Amarin
or view top insider-selling stocks.

Which major investors are buying Amarin stock?

AMRN stock was purchased by a variety of institutional investors in the last quarter, including Private Advisor Group LLC, Avantax Advisory Services Inc., and Hayek Kallen Investment Management.
View insider buying and selling activity for Amarin
or or view top insider-buying stocks.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $5.00.

How much money does Amarin make?

Amarin has a market capitalization of $1.98 billion and generates $614.06 million in revenue each year. The biopharmaceutical company earns $-18 million in net income (profit) each year or ($0.05) on an earnings per share basis.

How many employees does Amarin have?

Amarin employs 2,020 workers across the globe.

Does Amarin have any subsidiaries?

The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.

When was Amarin founded?

Amarin was founded in 1991.

What is Amarin's official website?

The official website for Amarin is www.amarincorp.com.

Where are Amarin's headquarters?

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at [email protected].

This page was last updated on 10/24/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.